Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 3/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13101678 | 0.95 | ALDH1A1 (0.43) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13102070 | 0.94 | SMN1; SMN2 (0.42) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13102086 | 0.93 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13102083 | 0.93 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13101679 | 0.92 | PDE1C (0.44) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13102286 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL29830753 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13102089 | 0.87 | P2RX7 (0.42) | SMN1; SMN2KDM4EPOLBMEN1KMT2A | |
| SCHEMBL14515545 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 | |
| SCHEMBL13102313 | 0.84 | ALDH1A1 (0.50) | SMN1; SMN2MAPK1TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663237-B1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7741332-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1663237-A4 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7223768-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1663237-A2 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005025293-A2 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059823-A1 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885MAPK1 1243/4885TSHR 1918/4885 |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885MAPK1 1243/4885TSHR 1918/4885 |
| US-20050059823-A1 | Fused ring heterocycles as potassium channel modulators | KCNK17, KCNJ2, KCNJ1 | SMN1; SMN2 253/4885MAPK1 1243/4885TSHR 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.